Beam Therapeutics Q2 net loss widens to $122.7 million as license revenue falls
Beam Therapeutics reported second quarter 2026 results on August 4, 2026. Net loss widened to $122.7 million, or $1.18 per share, from $102.1 million, or $1.00 per share, a year earlier, while license and collaboration revenue fell to $490,000 from $8.5 million. The company said it ended the quarter with $1.2 billion in cash and marketable securities and expects that cash, plus an additional $200 million from its Sixth Street facility, to fund operations into mid-2029.
Key points
- Net loss of $122.7 million, or $1.18 per share, for Q2 2026, versus $102.1 million, or $1.00 per share, for Q2 2025
- License and collaboration revenue of $490,000 for Q2 2026, versus $8.5 million for Q2 2025
- R&D expenses of $95.1 million and G&A expenses of $31.9 million in Q2 2026
- Cash, cash equivalents and marketable securities of $1.2 billion at June 30, 2026; runway expected into mid-2029
The filing
Written by AI on Nov 9, 2026, 8:53 AM ET, from this filing only. Written later: this filing was briefed after the fact, when past filings were added to the site, so the brief may be read with hindsight; the filing itself is the record of what was known on August 04, 2026.
Briefs are written by AI from the filing text and can contain mistakes — open the filing before acting on anything. Impact (1-5) and tone are the AI's reading of the filing for shareholders, not a price forecast. Not investment advice.